Plain-English translation of NCT06856343 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This is an observational study—meaning researchers will follow your real-world experience rather than testing something new. The study is tracking patients with early-stage, HER2-negative breast cancer who are prescribed Olaparib, a medication taken after surgery to help reduce the risk of cancer returning. Researchers want to understand how many people are able to complete their full course of this medication and identify any challenges that make treatment difficult.
Doctors know this medication can help some patients, but they need real-world information about how well people actually stick with their treatment plans. Understanding completion rates and any barriers to finishing the medication will help doctors and patients prepare better and improve outcomes.
You likely qualify if…
You likely don't qualify if…
You would continue taking the medication exactly as your doctor prescribes—nothing changes about your actual treatment. Researchers will simply check in with you periodically (the frequency is not specified in the trial details) to track whether you're completing your prescribed course and gather information about your experience. This might involve brief visits or phone calls to answer questions about how your treatment is going.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France